FF-21101 (90Y)

**FF-21101 (90Y)** is an investigational P-cadherin-targeted radioimmunotherapy for advanced solid tumors. It consists of a chimeric anti-cadherin-3 monoclonal antibody labeled through the DOTA chelator with the beta-emitting radionuclide yttrium-90. Following intravenous administration, it binds cadherin-3 on tumor cells and delivers localized cytotoxic beta radiation. A phase 1 study and expansion cohorts in advanced solid tumors, including ovarian carcinoma, were completed; the expansion study did not meet its predefined efficacy threshold and was ended. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/yttrium-y-90-anti-cdh3-monoclonal-antibody-ff-21101))

Other names

90Y-FF-21101yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101yttrium-90 FF-21101yttrium90 FF-21101yttrium 90 FF-21101